TO THE EDITOR:
The recent paper (1) denigrating the use of singlespecimen FOBT done at an office visit compared with a mail-in multiple-specimen test failed to take into account an important factor: adherence. It would appear to be only common sense that a test with relatively low sensitivity (and also specificity!) would have a higher yield when done on multiple specimens, as was the main point of the paper.
I switched to in-office testing when I realized that most of my patients who were given take-home kits failed to return the kits. The sensitivity of a test never done is zero. As Dr. Sox is also doubtless aware, the value of FOBT itself is questionable, and in 2005 we should be recommending colonoscopies regardless of the stool results.
We read with interest the article by Collins and colleagues (1) and the accompanying editorial by Dr. Sox (2) . We share Dr. Sox's concern that colorectal cancer mortality rates have not decreased more rapidly, considering the emphasis on increased screening over the past 10 years. We think this is multifactorial, and we would like to respond to these observations before the officebased FOBT is abandoned.
One reason for the slow decline might be the replacement of flexible sigmoidoscopy with total colonoscopy for people at low risk for colorectal cancer. With the exception of the Veterans Administration health system, this practice has produced a chasm between those who can afford total colonoscopy or insist on it versus those who cannot. A paucity of any screening intervention in the AfricanAmerican and Hispanic populations is troubling because available data show that colon cancer is diagnosed more frequently in AfricanAmerican and Hispanic persons than in white persons (3, 4) .
One reason for this failure in these populations may be the abandonment of FOBT. Collins and colleagues stressed that a single analysis of stool obtained by rectal examination showed a very low Letters sensitivity for the detection of advanced neoplasia when compared with analysis of 3 stools spontaneously passed. The authors do not stress the fact that FOBT is done annually and that many of these advanced neoplasms would be picked up on subsequent annual examinations, no matter what type of stool is tested. We therefore support any and all FOBT, with the caveat that a digital rectal examination should be considered sufficient for screening only if stool is obtained and that stool obtained by using this method should not be tested if visible blood is present. Some screening is better than no screening at all.
Christian Jackson, MD Robert Craig, MD Northwestern University Chicago, IL 60611
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IN RESPONSE:
In response to Dr. Wolff and Dr. Hoffer, I can but elaborate on my editorial. One concern is using office guaiac in lieu of other, better tests, which is common practice, according to Nadel and colleagues' survey (1) . A second concern is placing too much weight on a negative result on a test that misses 95% of colonic neoplasia. The third concern is inefficient use of invasive follow-up tests. The office guaiac has a positive likelihood ratio of 1.68 (2) , which means that the probability of high-risk neoplasia rises from 7.0% to 12% after a positive test result, which means doing 8.5 negative follow-up colonoscopies for every positive colonoscopy. When the 6-sample home test is used, the probability would rise from 7.0% to 35%, which would require fewer than 3 colonoscopies to detect an important lesion. Ultimately, physicians must develop better office systems to support home testing and identify nonadherent patients.
I only partially agree with Drs. Jackson and Craig. Fecal occult blood testing using 6 samples obtained at home is an important test because, coupled with colonoscopy when results are positive, it reduces mortality from colorectal cancer from 8.83 deaths per 1000 over 13 years to 5.88 deaths per 1000 (3). It's not a perfect test. Its sensitivity of 23.5% is very poor, so that it generates many negative colonoscopies. But it does reduce colorectal cancer death rates, which is more than you can say for sure about any other colorectal cancer screening test, least of all the office guaiac. We should advocate home testing, and we should develop office systems to help us raise adherence rates to a test that reduces colorectal cancer rates substantially.
Is a bad screening test better than none at all? Now there's a good subject for debate! TO THE EDITOR: Dr. Berwick (1) writes with insight on some of the important inefficiencies and flaws in our system, but I fear his attitude speaks louder than his words. Gandhi appears several times in the article as if to provide an approving stamp of compassion, and Berwick calls for better care not only for his knee but for a "Thai with dengue or an African with AIDS." But his is not a universal prescription for care; it is a prescription for grease to the squeaky wheel. He needs an appointment "any day [he] want[s] it" because he is "really busy" and cannot wait, yet at the same time he wants all his questions answered to his full satisfaction. He is like the patient who stomps his foot angrily when the doctor is running late but then stays in the examining room for 1 hour dissecting his concerns while other patients-perhaps including the Thai and the African-languish in the waiting room. This is part of human nature, but it does not lend itself to a just and universal health care system. To add injury to injury, Berwick asks for no needless deaths or pain, yet in his own nonmedical life he has courted both by climbing Mount Rainier 5 times. Woe to the poor knees.
Berwick seems to be one of the many medical consultants who believe that aping business models is the only way to save U.S. medicine. He quotes glowingly Paul O'Neill and his idea of a "habit of excellence," the same O'Neill who has presided over the decline of the U.S. economy over the past several years. Medicine can never be truly run like a business: One does not refuse to serve the customer in the emergency department because he cannot pay. Berwick's hybrid model, which to me looks something like a Wal-Mart staffed by Gandhis, may appear to be an answer to him, but I remain unconvinced.
Benjamin L. Sapers, MD Rhode Island Hospital Providence, RI 02903
Letters TO THE EDITOR: Although the application of the "total quality" method might seem appropriate to medicine, one fundamental problem exists. The "quality movement" is, of course, a concept borrowed from business models, which can be traced back to Deming's seminal work (1) . However, there is a critical difference between U.S. medicine and other businesses that makes Dr. Berwick's search (2) a fool's errand. Specifically, "total quality" was primarily intended as a method to increase sales and profits in a business operating in the free market, and U.S. health care is simply not a free market.
According to 2001 data from the Organisation for Economic Co-operation and Development data, health care accounts for 13.9% of the gross domestic product, and 44.6% of health care expenditures in the United States were paid by public systems such as Medicare, Medicaid, the Veterans Administration and other military care, public health clinics, and other programs (3). However, when one includes tax subsidies and public employee benefits, the current taxfinanced share of health spending is nearly 60% (4). Government mandates and regulations add another layer of public expense to health care in the United States. From 1970 to 1996, state and federal mandates increased 25-fold, an annual growth rate of 15% (5). Thus public spending, not private outlays, already pays the majority of U.S. health costs. This is an important distinction because the U.S. government sets prices (from doctor's fees to hospital stays) for its Medicare and Medicaid programs. Fixing prices for an industry, while intended to reduce outlays, removes the essential information provided by prices, which best reflect supply and demand. This imposes "the impossible burden" of replacing the intricate information available through prices with a centralized bureaucracy that must somehow learn what people want and provide it by orders and protocols (6) . In contrast to price rationing present in the free market, health care outlays under Medicare and Medicaid are rationed by means other than price, such as waiting lists, drug formularies, limited treatment options, and discrimination by age or disease. Additional effects of nonprice rationing (that is, fixed prices) include underfunding, shortages, delayed diagnosis and treatment, reduced quality, and health worker strikes (7) . As a result, investment and rewards are not determined by meeting patient needs but instead by surviving the belowcost payments offered by the government, achieved by shifting those costs onto younger insured patients (a method becoming less and less available).
For the health care competition that does exist in the United States, the incentives are skewed to favor innovations that raise costs or increase quality regardless of expense. These incentives discourage cost sensitivity for patients while providers are encouraged to increase services, maximize reimbursement, make expensive referrals, and practice defensive medicine.
In short, incentives matter, and the incentives of the current U.S. health care system are unable to create the "total quality" system desired by the author. The problem is one of basic economics, not a lack of "energy, insight, and courage." Attempts to change human behavior through rousing admonitions rather than improved incentives are doomed to failure. 
Regulation of Body Weight by Proopiomelanocortin Peptides in Humans: Lessons from the Nelson Syndrome

TO THE EDITOR: Background: Melanocortins (␣-melanocyte-stimulating hormone [MSH] and adrenocorticotropic hormone [ACTH])
, in addition to their melanocyte-stimulating actions, may regulate energy balance through hypothalamic melanocortin-4 receptors (MC4Rs). In mice, deletion of the proopiomelanocortin (POMC) or MC4R genes leads to obesity, whereas administration of MC4R agonists (for example, MSH) causes weight loss (1) . In humans, inactivating mutations of the POMC (2) or MC4R (3) genes can cause obesity, but there is no evidence that increased melanocortin action can cause weight loss.
In the Nelson syndrome, rapid growth of an adrenocorticotrophic pituitary adenoma following bilateral adrenalectomy causes extreme elevation of melanocortin levels and hyperpigmentation. The Nelson syndrome is a human model in which temporal associations among body weight, skin pigmentation, and high circulating levels of melanocortins might be observed.
Objective: To investigate these associations, we tracked body weight, hormone levels, and intensity of skin and scar pigmentation over 20 years in a patient with the Nelson syndrome.
Case Report: In 1982, a previously healthy 29-year-old woman experienced weight gain and was treated unsuccessfully with gastric stapling in 1983. In early 1984, she developed biochemical evidence of the Cushing syndrome and underwent unilateral adrenalectomy for an adrenal nodule. The contralateral adrenal gland was removed in late 1984 because of persistent hypercortisolemia, and physiologic replacement of hydrocortisone and fludrocortisone was started. In 1987, after attaining her peak body mass (body mass index, 44.7 kg/m 2 ), the patient experienced pronounced skin darkening and lost 37.3 kg (body mass index, 27.6 kg/m 2 ), followed by headaches and bitemporal hemianopsia. Diagnosis of the Nelson syndrome with pituitary macroadenoma and elevated plasma ACTH levels (6000 pg/mL [normal value, Ͻ65 pg/mL]) led to partial transsphenoidal tumor resection in late 1988. All symptoms resolved, followed over the next year by a weight gain of 7.3 kg with skin lightening. Six years later, in 1994, the Nelson syndrome recurred, with marked skin darkening, a weight loss of 7.5 kg, headaches, and hemianopsia; the patient underwent a second transsphenoidal resection. The pituitary tumor contained both ACTH and MSH on immunohistochemical analysis. Plasma ACTH levels then decreased, associated with weight gain (8.2 kg), lightening of the skin, and resolution of all symptoms. Since 1995, the patient's weight, skin color, and health have remained stable. Euthyroidism and euglycemia were noted The intensity of pigmentation in scars formed at different times also varied inversely with weight changes. Scars from the gastric stapling and adrenalectomies that predated the Nelson syndrome (and that formed as the patient gained weight) were pale, indicating that contemporaneous melanocortin levels were not excessive, consistent with the normal plasma ACTH levels in 1985 and early 1987 (Figure) . In contrast, scars from a gastric stapling reversal procedure (late 1987) and the pituitary resection (1988), which formed as the patient lost weight, were dark. A scar from a minor injury in 1991, which formed as the patient gained weight, was pale, indicating that circulating melanocortin levels were not excessive in this period, whereas the scar from the second pituitary resection in 1995, formed as the patient lost weight again, was dark because of supraphysiologic circulating melanocortin levels at that time. For photographs of the patient over time, see Appendix Figures 1 and 2 , available at www .annals.org.
Discussion: This patient's body weight fluctuations correlated inversely with plasma ACTH levels, suggesting that excessive ACTH (and ␣-MSH) secretion by the Nelson tumor could be responsible. Of importance, the data exclude confounding metabolic influences of altered glucocorticoid levels, which were effectively held steady by fixed glucocorticoid replacement therapy after total adrenalectomy. The dramatic decreases in body weight during the initial growth and later recurrence of the pituitary tumor suggest that endogenous circulating melanocortins, at least at supraphysiologic levels, can induce weight loss in humans.
The melanogenic actions of POMC products provided a striking interpretive tool in this case. Human melanocytes are highly sensitive to both MSH and ACTH, and melanocortin administration can cause skin darkening. Therefore, the intensity of eumelanin (dark) skin pigmentation was a temporal biomarker of supraphysiologic circulating melanocortin levels, supported by biochemical and immunocytochemical ACTH and MSH determinations. Furthermore, the increased melanization of dark scars provided a novel, permanent record of the excessive circulating melanocortin levels that prevailed during their formation, in contrast with the transient hyperpigmentation of normal skin. (Melanization of scars occurs weeks after wound formation and persists because of the negligible turnover and desquamation rates of scar keratinocytes relative to those in normal skin.) Conversely, the absence of melanization in scars that formed during periods of steady weight gain (1983 to 1984, 1991) indicates that the prevailing blood melanocortin levels at those times were not excessive.
Melanocortin neurons project to MC4R-rich hypothalamic nuclei implicated in appetite regulation (4); they also inhibit feeding and increase energy expenditure. In animals, MC4R agonists cause weight loss (1) and MC4R antagonists cause hyperphagia (5). Inactivating mutations of the POMC and MC4R genes in some obese humans (2, 3) indicate that blunted melanocortin signaling can cause weight gain, but there is little evidence for the converse phenomenon, or that changes in endogenous circulating melanocortin levels can dynamically alter body weight. This patient dramatically demonstrates such dynamic regulation, with the novel finding that excessive melanocortin production is associated with marked weight loss.
Conclusion: The repeated inverse correlations between plasma
